Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Green Valley to Start US Trial of Algae-based Alzheimer's Drug

publication date: Nov 5, 2020

Shanghai Green Valley Pharma announced its global Phase III trial of an algae-derived treatment for Alzheimer's disease has begun enrolling patients. The company intends to enroll 2046 patients with mild to moderate Alzheimer's in the US, China and Europe. The trial is expected to finish in 2024, even though the longest endpoint is based on 76 weeks of treatment. The US approved the Phase III trial in April, but the Covid pandemic delayed the start of the trial until now. Green Valley was approved to launch Oligomannate in China one year ago following trials there. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital